The ALDH7A1 antibody is a crucial tool for studying aldehyde dehydrogenase 7 family member A1 (ALDH7A1), a mitochondrial enzyme involved in lysine metabolism and cellular detoxification. ALDH7A1 catalyzes the oxidation of α-aminoadipic semialdehyde (α-AASA) to α-aminoadipic acid, a critical step in the lysine degradation pathway. Deficiencies in ALDH7A1 cause pyridoxine-dependent epilepsy (PDE), a rare autosomal recessive disorder characterized by seizures resistant to conventional antiepileptics but responsive to vitamin B6 supplementation. Research using ALDH7A1 antibodies focuses on understanding its role in metabolic pathways, neuronal function, and disease mechanisms. These antibodies are widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression, localization, and quantification in tissues or cell lines. They help identify ALDH7A1 mutations in PDE patients and validate experimental models, such as knockout mice or cell cultures. Commercially available ALDH7A1 antibodies are typically raised in rabbits or mice against specific epitopes, with validation for specificity and cross-reactivity across species. Their application extends to diagnostic screening and biomarker studies, aiding in early PDE detection and therapeutic development. By enabling precise protein analysis, ALDH7A1 antibodies contribute to advancing metabolic disorder research and personalized medicine approaches.